Sabrina Serani

Preliminary results from the TRIFOUR trial highlight nadunolimab's potential in treating advanced triple-negative breast cancer, showing promising efficacy and safety.

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

Osimertinib plus chemotherapy significantly improves overall survival in EGFRm NSCLC, signaling a new standard of care.

Innovative research explores targeted therapies for early triple-negative breast cancer, aiming to reduce toxicity while enhancing treatment efficacy.

FDA issues a complete response letter for glofitamab's second-line DLBCL indication, highlighting ongoing scrutiny in oncology therapy approvals.

A phase 2 trial shows promising safety results for carotuximab in treating advanced prostate cancer, offering hope for patients with limited options.

FDA grants orphan drug designation to ICT01, a promising immunotherapy for acute myeloid leukemia, targeting unmet needs in older patients.

Promising results emerge from a phase 1b trial of azer-cel, an innovative CAR T-cell therapy, showing high response rates in DLBCL patients.

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, highlighting notable ocular toxicities and missed opportunities for dosing optimization.

Researchers explore glioblastoma's genetic complexity using innovative spatial profiling, aiming to enhance treatment strategies and understand tumor resistance.

Zenith Epigenetics' ZEN-3694 gains FDA fast track designation, offering hope for patients with aggressive NUT carcinoma through innovative treatment combinations.

Cancer care evolves as financial navigation becomes essential. Experts highlight the need for empathy, communication, and routine screenings to support patients effectively.

Agenus reveals promising survival rates for its immunotherapy in metastatic colorectal cancer, potentially transforming treatment for resistant patients.

This week’s edition of The Targeted Pulse spotlights 5 key developments shaping the landscape of targeted oncology.

In the MIDAS trial, ASCT showed no added MRD benefit over Isa-KRd in newly diagnosed myeloma, raising questions about transplant timing.

FDA's new draft guidance enhances drug development for myelodysplastic syndromes, focusing on trial design, patient selection, and safety reporting.

Adcentrx Therapeutics advances gastric cancer treatment with FDA orphan drug designation for ADRX-0405, a promising antibody-drug conjugate in clinical trials.

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant melanoma.

FDA designates MB-101 CAR T-cell therapy for glioblastoma, highlighting its potential in treating aggressive brain tumors with innovative combination strategies.

FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive malignancy.

Ruxolitinib shows sustained efficacy and safety in treating steroid-refractory chronic graft-vs-host disease, outperforming standard therapies over three years.

From FDA approvals streamlining access to critical therapies to new breakthroughs in challenging malignancies, the field of cancer care continues to demonstrate remarkable progress.

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with extensive-stage small cell lung cancer.

Discover groundbreaking advancements in GI cancer treatments from ASCO 2025, highlighting innovative therapies and improved patient outcomes.

Preliminary data highlights gedatolisib's potential in treating mCRPC and HER2+ mBC, showcasing promising efficacy and a favorable safety profile.

FDA accelerates approval of sunvozertinib for advanced NSCLC with EGFR mutations, offering new hope for patients after chemotherapy.